RT Journal Article SR Electronic T1 Household Transmission of SARS-COV-2: Insights from a Population-based Serological Survey JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.11.04.20225573 DO 10.1101/2020.11.04.20225573 A1 Qifang Bi A1 Justin Lessler A1 Isabella Eckerle A1 Stephen A Lauer A1 Laurent Kaiser A1 Nicolas Vuilleumier A1 Derek AT Cummings A1 Antoine Flahault A1 Dusan Petrovic A1 Idris Guessous A1 Silvia Stringhini A1 Andrew S. Azman A1 for the SEROCoV-POP Study Group YR 2020 UL http://medrxiv.org/content/early/2020/11/04/2020.11.04.20225573.abstract AB Importance Knowing the transmissibility of asymptomatic infections and risk of infection from household and community exposures is critical to SARS-CoV-2 control. Limited previous evidence is based primarily on virologic testing, which disproportionately misses mild and asymptomatic infections. Serologic measures are more likely to capture all previously infected individuals.Objective Estimate the risk of SARS-CoV-2 infection from household and community exposures, and identify key risk factors for transmission and infection.Design Household serosurvey and transmission model.Setting Population-based serosurvey in Geneva, SwitzerlandParticipants 4,524 household members five years and older from 2,267 households enrolled April-June 2020.Exposures SARS-CoV-2 infected (seropositive) household members and background risk of community transmission.Main outcomes and measures Past SARS-CoV-2 infection confirmed through anti-SARS-CoV-2 IgG antibodies by ELISA. Chain-binomial models based on the number of infections within households were used to estimate extra-household infection risk by demographics and reported extra-household contacts, and infection risk from exposure to an infected household member by demographics and infector’s symptoms. Infections attributable to exposure to different types of infectious individuals were estimated.Results The chance of being infected by a single SARS-CoV-2 infected household member was 17.2% (95%CrI 13.6-21.5%) compared to a cumulative extra-household infection risk of 5.1% (95%CrI 4.5-5.8%). Infection risk from an infected household member increased with age, from 7.5% (95%CrI 1.3-20.3%) among 5-9 years to 30.2% (95%CrI 14.3-48.2%) among those ≥65 years. Working-age adults (20-49 years) had the highest extra-household infection risk. Seropositive household members not reporting symptoms had 74.8% lower odds (95%CrI 43.8-90.3%) of infecting another household member compared to those reporting symptoms, accounting for 19.6% (95%CrI 12.9-24.5%) of all household infections.Conclusions and Relevance The risk of infection from exposure to a single infected household member was four-times that of extra-household exposures over the first wave of the pandemic. Young children had a lower risk from infection from household members. Asymptomatic infections are far less likely to transmit than symptomatic ones but do cause infections. While the small households in Geneva limit the contribution of household spread, household transmission likely plays a greater role in other settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study grants from Swiss Federal Office of Public Health, Swiss School of Public Health (Corona Immunitas research program), Fondation de Bienfaisance du Groupe Pictet, Fondation Ancrage, Fondation Privee des Hopitaux Universitaires de Geneve, and Center for Emerging Viral Diseases. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Cantonal Research Ethics Commission of Geneva, Switzerland (CER16-363). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode to reproduce analyses will be posted on github (https://github.com/HopkinsIDD/serocovpop-households) and data will be made available upon request to the corresponding author. https://github.com/HopkinsIDD/serocovpop-households